Tags: Drug.
Pegdinetanib (USAN; planned trade name Angiocept) is an investigational anti-cancer drug that acts as a selective antagonist of vascular endothelial growth factor receptor 2 (VEGFR-2) hindering vascularization of tumors. It is a genetically engineered peptide derivative based on the monobody technology and is being developed by Adnexus.The drug has entered Phase II clinical trials investigating the treatment of glioblastoma in October 2007.
